Definium Therapeutics to present Phase 3 Panorama topline data for DT120 in generalized anxiety disorder Sept. 14
DFTX•Webcast set for Sept. 14
Definium Therapeutics scheduled a Sept. 14, 2026 webcast to discuss topline results from its Phase 3 Panorama study in generalized anxiety disorder.
Results have not yet been presented; the company plans to release the topline readout during the event.
The update will cover Panorama, the second Phase 3 trial of DT120 (lysergide) orally disintegrating tablet in adults with the condition.
